New Data Brings Yescarta Closer To Blockbuster Territory
Potential Market Adds 14,000 US Patients
Gilead announced positive topline results from the ZUMA-7 trial of Yescarta in second-line large B-cell lymphoma, where the CAR-T would eventually compete with BMS’s Breyanzi and Novartis’ Kymriah.
